Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma

• Published in: British journal of obstetrics and gynaecology Vol. 97; no. 4; p. 342
• Main Authors: Masding, J, Sarkar, T K, White, W F, Barley, V L, Chawla, S L, Boesen, E, Rostom, A Y, Menday, A P
• Format: Journal Article
• Language: English
• Published: England 01.04.1990
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Busulfan - administration & dosage; Busulfan - adverse effects; Busulfan - analogs & derivatives; Busulfan - therapeutic use; Cisplatin - administration & dosage; Cisplatin - adverse effects; Female; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate
• ISSN: 0306-5456
• DOI: 10.1111/j.1471-0528.1990.tb01813.x

In a prospective, multicentre, randomized trial, the efficacy and tolerance of treosulfan alone was compared with that of treosulfan plus cisplatinum in 135 women with advanced ovarian carcinoma. No statistically significant difference was found between the two treatments in terms of median survival. Combined treatment was associated with significantly greater side-effects and haematological toxicity. Optimal survival with minimal toxicity can be achieved by using treosulfan alone in patients (mainly stages Ic or II) with minimal postoperative residual disease. Patients (likely to be stage III or IV) with greater residual disease should receive treosulfan plus cisplatinum.